What do you get when you insert a molecular glue degrader into an antibody-drug conjugate (ADC)? Fortitude Biomedicines is in ...

The ex-CytoDyn chief exec must also forfeit more than $4.4 million—approximately the amount he profited from the scheme—and ...

AstraZeneca is showing no signs of restarting a 200 million pound sterling ($273 million) investment in its U.K. hometown, ...

European investment firm Gimv will no longer put funds into the life sciences sector, choosing instead to focus on its ...

The industry has learned how the ball bounces—now it must decide where to play next.  | While 2025 was dedicated to “understanding a little bit more about the rules of this game that we’re playing,” ...

Guardant’s test analyzes circulating tumor DNA that is then used to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with the Braftovi combo therapy ...

A federal grand jury in Rhode Island has charged two former top executives of Colorado-based medical device company Zynex Inc. | A federal grand jury in Rhode Island has charged two former top ...

Fast-forward to 2026, and we’ve already seen a handful of U.S. biotechs line up to squeeze through a gradually reopening IPO ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

In a reminder of the money still on the table for enticing obesity assets, Corxel Pharmaceuticals has raised $287 million in ...

Sanofi has reported mixed phase 3 data on amlitelimab, further muddying the prospec | Sanofi has reported mixed phase 3 data ...

T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells. The modality has remained a big draw for Big Pharma, with Eli Lilly penning ...